MediWound’s (MDWD) “Buy” Rating Reiterated at HC Wainwright

MediWound (NASDAQ:MDWD)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $28.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 37.73% from the company’s current price.

MDWD has been the subject of several other reports. Maxim Group upped their price objective on shares of MediWound from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday. StockNews.com raised MediWound to a “sell” rating in a research report on Wednesday, July 3rd.

MediWound Price Performance

NASDAQ MDWD opened at $20.33 on Tuesday. The firm has a market cap of $188.74 million, a P/E ratio of -14.73 and a beta of 0.81. The stock’s 50-day moving average is $16.79 and its two-hundred day moving average is $15.34. MediWound has a fifty-two week low of $7.10 and a fifty-two week high of $24.00.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Wednesday, May 29th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. The business had revenue of $4.96 million for the quarter, compared to the consensus estimate of $4.65 million. MediWound had a negative return on equity of 21.67% and a negative net margin of 64.24%. On average, equities analysts expect that MediWound will post -1.93 EPS for the current year.

Institutional Trading of MediWound

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Rosalind Advisors Inc. lifted its stake in shares of MediWound by 5.7% in the second quarter. Rosalind Advisors Inc. now owns 513,490 shares of the biopharmaceutical company’s stock valued at $7,969,000 after buying an additional 27,500 shares during the period. Essex Investment Management Co. LLC raised its holdings in MediWound by 241.6% in the 1st quarter. Essex Investment Management Co. LLC now owns 132,487 shares of the biopharmaceutical company’s stock valued at $1,888,000 after acquiring an additional 93,705 shares in the last quarter. Janney Montgomery Scott LLC bought a new stake in shares of MediWound in the 1st quarter worth approximately $427,000. Silverberg Bernstein Capital Management LLC grew its holdings in shares of MediWound by 7.8% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 85,184 shares of the biopharmaceutical company’s stock worth $1,214,000 after purchasing an additional 6,200 shares in the last quarter. Finally, Yelin Lapidot Holdings Management Ltd. increased its position in shares of MediWound by 45.7% during the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 125,493 shares of the biopharmaceutical company’s stock valued at $1,276,000 after purchasing an additional 39,348 shares during the period. 46.83% of the stock is currently owned by institutional investors and hedge funds.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.